Welcome to the Gastrointestinal (GI) Cancer Drug Development Summit
This conference is focused on optimizing your clinical program in targeted, immune, ADC and combination therapies. Discover how leaders in the space are improving clinical trial design, precision oncology, patient groups and more to beat the long-standing disparity of where gastrointestinal drugs are and where GI drugs should be.
Building on recent progress and approvals for targeted and immunotherapy agents in GI cancer indications, join the only biopharma-led forum to learn from industry pioneers, network with key decision-makers and identify the next therapeutic opportunities for GI cancer drug development.
Key 2021 Discussions Included:
Delve into discussions and case studies from experts in identifying and advancing promising solid tumor therapeutics to pursue in GI cancer indications with Sandhill Therapeutics, Genentech, Sanofi Genzyme & Revolution Medicines
Discover the world of developing a clinical program for targeted and immunotherapies in GI with Mirati Therapeutics, Kinnate, Elevation Oncology, AUM Biosciences, Zymeworks, Maverick Therapeutics, Pieris Pharmaceuticals & Merck Kgaa
Dive into the world of ctDNA and learn how to optimize it as a tool for diagnosis, prognosis and therapeutic response in GI cancer patients with researchers from Boundless Bio, MD Anderson, IMD Diagnostics & SBIR/NCI/NIH
Explore optimal clinical trial development, design and case studies from clinical trial leaders at the NHS, AstraZenca & UT Southwestern
Optimize application and patient outlook through combination strategies, patient groups, early detection and emerging biomarkers with BloodPAC, Pfizer & Health Collaborations LLC